Avalo Therapeutics, Inc. Common Stock AVTX
$7.45
-39.23%
at last close
Market Cap$657.50 million
P/E Ratio—
Div Yield—
Volume26.19M
52-Week Range
$6.85$24.27
Analyst Ratings
- Consensus
- Buy — 10 Buy · 0 Hold · 0 Sell (10 analysts)
- Avg. Price Target
- $45.10 (+505.4% upside)
Key Stats
- Today's Range
- $6.85 – $9.35
- 50-Day Range
- $6.85 – $21.02
- 52-Week Range
- $6.85 – $24.27
- Volume
- 26.19 million shs
- Average Volume
- 2.05 million shs
- Market Cap
- $657.50 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 4.95%
- Days to Cover
- 5.48
About Avalo Therapeutics, Inc. Common Stock
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Related Stocks
Compare head-to-head: AVTX vs LLY·AVTX vs JNJ·AVTX vs ABBV·AVTX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.